Center for Biomedicine and Medical Technology Mannheim, Medical Faculty Mannheim, University of Heidelberg, Germany.
Curr Med Res Opin. 2013 May;29(5):527-38. doi: 10.1185/03007995.2013.781019. Epub 2013 Mar 21.
The capsaicin 8% cutaneous patch is an emergent new treatment option for patients with peripheral neuropathic pain. In randomized controlled clinical studies relevant pain relief for 12 weeks was achieved in about one third of patients following a single application. The first part of this paper is a review of the pathophysiology, pharmacology, and published clinical trials with the capsaicin 8% cutaneous patch. The second part reports on outcomes of an interdisciplinary expert workshop, where new treatment results of three major German pain centers were presented and reviewed with the objectives of obtaining responder rates for different pain syndromes, assessing maintenance of effect under real-life conditions, and giving recommendations for practical care. The 12 week responder rates with pain relief of ≥ 30% were comparable in patients with mononeuropathies (37.9%) and postherpetic neuralgia (38.8%). Similar responder rates were seen in a subgroup of patients with cervical spine radiculopathy and back pain (46.7%). In HIV-associated neuropathy the responder rates were high (47.8%) but lower in patients with other polyneuropathies (17.6%). Response rates were nearly identical after 1 week (46.6%) and 4 weeks (43.3) and dropped only slightly at 12 weeks (37.4%). In a subgroup of 54 patients who underwent a second treatment, efficacy was maintained. Response rates in patients with or without lidocaine pretreatment were comparable. Treatment with the capsaicin 8% cutaneous patch was generally safe and well tolerated. The workshop panel recommended further investigation of opportunities to improve the application procedure and to perform studies on the skin penetration and distribution of capsaicin. A modified quantitative sensory testing (QST) should be developed for clinical practice in order to better understand the correlation of sensory profiles and response to capsaicin treatment.
辣椒素 8%贴剂是一种新兴的外周神经病理性疼痛治疗选择。在相关的随机对照临床试验中,单次应用后约三分之一的患者可获得 12 周的缓解疼痛。本文第一部分是对辣椒素 8%贴剂的病理生理学、药理学和已发表的临床试验的综述。第二部分报告了一个跨学科专家研讨会的结果,会上介绍了三个德国主要疼痛中心的新治疗结果,并对其进行了评估,目的是获得不同疼痛综合征的应答率、评估实际生活条件下的疗效维持情况,并为实际护理提供建议。在单神经病(37.9%)和带状疱疹后神经痛(38.8%)患者中,疼痛缓解≥30%的 12 周应答率相当。在颈神经根病和背痛患者(46.7%)的亚组中也观察到相似的应答率。在 HIV 相关神经病中,应答率较高(47.8%),但在其他多发性神经病患者中较低(17.6%)。在第 1 周(46.6%)和第 4 周(43.3%)时,应答率几乎相同,而在第 12 周时仅略有下降(37.4%)。在 54 名接受第二次治疗的患者亚组中,疗效得以维持。有或没有利多卡因预处理的患者的应答率相当。辣椒素 8%贴剂治疗通常安全且耐受良好。专家组建议进一步研究改善应用程序的机会,并对辣椒素的皮肤渗透和分布进行研究。应开发一种改良的定量感觉测试(QST),以便更好地理解感觉特征和对辣椒素治疗的反应之间的相关性。